rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
11
|
pubmed:dateCreated |
2008-11-4
|
pubmed:abstractText |
Inhaled hypertonic saline (HS) improves lung function and decreases pulmonary exacerbations in older patients with cystic fibrosis (CF). Initiating therapies in young patients has potential to preserve lung function. Before conducting a therapeutic trial of HS in this population, its safety must be evaluated and protocols for monitoring response must be tested.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1099-0496
|
pubmed:author |
|
pubmed:copyrightInfo |
(c) 2008 Wiley-Liss, Inc.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
43
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1100-6
|
pubmed:meshHeading |
pubmed-meshheading:18828160-Administration, Inhalation,
pubmed-meshheading:18828160-Albuterol,
pubmed-meshheading:18828160-Bronchodilator Agents,
pubmed-meshheading:18828160-Child,
pubmed-meshheading:18828160-Child, Preschool,
pubmed-meshheading:18828160-Cystic Fibrosis,
pubmed-meshheading:18828160-Drug Therapy, Combination,
pubmed-meshheading:18828160-Female,
pubmed-meshheading:18828160-Humans,
pubmed-meshheading:18828160-Infant,
pubmed-meshheading:18828160-Male,
pubmed-meshheading:18828160-Respiratory Function Tests,
pubmed-meshheading:18828160-Saline Solution, Hypertonic,
pubmed-meshheading:18828160-Surface-Active Agents
|
pubmed:year |
2008
|
pubmed:articleTitle |
Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis.
|
pubmed:affiliation |
Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7217, USA. elisabeth_dellon@med.unc.edu
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|